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Abstract
Background: In Asia, over 50% of patients with symptoms of tuberculosis (TB) access health care from private
providers. These patients are usually not notified to the National TB Control Programs, which contributes to low
notification rates in many countries.
Methods: From January 1, 2011 to December 31, 2012, Karachi’s Indus Hospital - a private sector partner to the
National TB Programme - engaged 80 private family clinics in its catchment area in active case finding using health
worker incentives to increase notification of TB disease. The costs incurred were estimated from the perspective of
patients, health facility and the program providing TB services. A Markov decision tree model was developed to
calculate the cost-effectiveness of the active case finding as compared to case detection through the routine
passive TB centers. Pakistan has a large private health sector, which can be mobilized for TB screening using an
incentivized active case finding strategy. Currently, TB screening is largely performed in specialist public TB centers
through passive case finding. Active and passive case finding strategies are assumed to operate independently
from each other.
Results: The incentive-based active case finding program costed USD 223 per patient treated. In contrast, the
center based non-incentive arm was 23.4% cheaper, costing USD 171 per patient treated. Cost-effectiveness analysis
showed that the incentive-based active case finding program was more effective and less expensive per DALY
averted when compared to the baseline passive case finding as it averts an additional 0.01966 DALYs and saved
15.74 US$ per patient treated.
Conclusion: Both screening strategies appear to be cost-effective in an urban Pakistan context. Incentive driven
active case findings of TB in the private sector costs less and averts more DALYs per health seeker than passive case
finding, when both alternatives are compared to a common baseline situation of no screening.
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Background
In Asia efforts to strengthen tuberculosis (TB) care are
concentrated in the public sector even though over 50%
of patients with symptoms of TB access health care from
private sector [1–3]. Private general practitioners (GPs)
are often preferred as they are easily accessible and offer
flexible hours of service compared to public sector facil-
ities [4]. These individuals, if diagnosed with TB, are
often not notified to the National TB Control Programs
(NTPs), and therefore reduces notification rates in many
countries. To identify TB patients being treated in the
private sector, public programs have worked with private
providers utilizing strategies such as active case finding
and incentives for health workers [5–8].
The effectiveness of involving the private sector to iden-
tify people with TB has been demonstrated [9, 10], though
with limited data on its cost-effectiveness [11, 12]. TB
programs have used incentives to keep the private sector
engaged for improved case finding, expand access to treat-
ment and to improve outcomes. However, there has been
diverging results with some studies showing benefits from
incentives and others no benefits [13–15]. In addition,
very limited information is available on cost-effectiveness
of the incentives to the health care providers to increase
case notification as part of active case finding programs.
Pakistan ranks fifth amongst TB high-burden countries
worldwide. It accounts for 61% of the TB burden in the
WHO Eastern Mediterranean Region, yet only 58% of
the estimated people with TB are detected and notified
through the standard passive system [16]. It is speculated
that many of these missing TB cases are treated in the
private sector. Indus Hospital, a private sector hospital
based in Karachi, engaged private providers and pro-
vided incentives to health worker in its catchment area
to increase TB case detection [17]. All TB patients were
notified to the NTP, and received standard of care from
their neighborhood GP provider. This study estimated
the cost- effectiveness of this active case finding program
in the private sector using incentives as compared to the
existing passive case finding and treatment program.
Methods
Setting
In Pakistan general health care services are delivered by
two parallel, independent and competing public and
private health systems. The public sector provides free
consultation at outpatient level but patients have to pay
for their medications, whereas, the private sector
operates as a fee for service system. An estimated 67.4%
households in Pakistan consult private health providers
when they need medical services with the province of
Sindh leading at 78.93% [18].
The study was conducted in Korangi Town, one of 18
towns of Karachi, Sindh, and consisted of both active
case finding (ACF) and passive case finding (PCF). The
PCF was based at the Indus Hospital, which is a private
not for profit tertiary care hospital that provides free
quality health care services to patients. The hospital is
primarily funded through donations and serves an esti-
mated population of 800,000 people from all five major
ethnic groups of Pakistan, mostly lower-income house-
holds. The TB clinic at the Indus Hospital is part of the
standard TB treatment and reporting system in Pakistan.
It provides care to 150–200 walk-in patients daily who
presents themselves with symptoms of TB. Patients are
investigated with smear microscopy, Xpert MTB/RIF
assay and chest x-rays. If diagnosed, they are treated and
reported based on the national TB program guidelines.
ACF was conducted for 2 years from January 1, 2011
to December 31, 2012. Indus Hospital’s TB outreach
program created a network of over 80 stand-alone
private family clinics in its catchment population to in-
crease TB case detection and treatment for TB. The
family clinics were selected based on their geographical
dispersion, high patient load and proximity to high-risk
population.
The active case finding included monetary and non-
monetary incentives to both health workers and the fam-
ily doctors providing the treatment. A project-employed
health worker was stationed at each of the family clinics
to verbal symptom screen all patients and their atten-
dants seeking health care for any illness and refer people
with potential TB symptoms for further evaluation by
the family physician which included smear microscopy,
Xpert MTB/RIF assay and chest x-rays. The health
workers received a fixed monthly stipend and perform-
ance based incentive payment for submitting a daily
phone report ($0.18 per report), procuring an acceptable
sputum sample ($0.88), and identifying a smear-positive
case ($11.80) or other form of tuberculosis ($5.88). Add-
itional incentives were provided for treatment initiation
($1.76) and each follow-up visits ($0.58).
The family clinic doctors received non-monetary in-
centives such as communication material, height charts,
weighing scales and advertisement on local cable chan-
nels that increased the publicity of the clinic. The pro-
gram also conducted a media campaign using billboards,
banners, pamphlets, posters, and short advertisements
on local cable television channels. The message focused
upon the need for anyone with over 2 weeks of product-
ive cough to seek free testing and free treatment at
either the Indus hospital or associated family clinics. All
patients were provided free diagnostics and treatment as
per the national TB program guidelines. Individuals
enrolled in both arms were assigned unique identifiers.
A total of 129 participants who were included in the
costing study were randomly selected from 859 patients
in passive arm and 1858 patients in the active arm that
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had been on treatment for a minimum of 2months
during the same time frame. Out of these 129 patients
who were interviewed for out of pocket expenditure they
incur in the process of seeking TB care, 45 received
treatment at the Indus hospital and the remaining 84 at
the private family clinics. There was no cross over of
patients between the 2 arms.
Notification data
Data were collected on all people with presumptive TB,
smear microscopy conducted, people diagnosed with TB
and treatments initiated. Treatment outcomes (cure, loss
to follow up and death) were collected from the routine
reporting system of the NTP. On average loss to follow
up occurred at month 3 and death at month 4 for this
cohort. As we did not have outcome information on pa-
tients transferred out to other treatment centers, they
were considered as loss to follow up by our study [19].
Cost data
We collected data on the direct costs from the perspective
of the patients, health facilities and the TB program, as
well as indirect costs from the patients’ perspective. The
patient cost collection tool used in this study was adapted
from a World Bank questionnaire on economic impact of
adult fatal illness [20]. This tool was adapted for TB and
has been used in multiple TB cost studies in Canada, Haiti
and Dominican Republic [21–24]. The questionnaire was
translated into Urdu and pilot-tested. We recruited an ex-
perienced team of field workers and trained them in inter-
view ethics, techniques and procedures. After verbal
informed consent, interviews were conducted at home
after treatment initiation. The data capture was electronic
on smart phones using an open-source Open Data Kit
(ODK) platform. Quality control procedures were put in
place through regular field supervision of interviewers and
daily review of collected data.
The patient’s costs were estimated at three points of
time, including when they sought care for the TB symp-
toms (pre-diagnosis), at diagnostic visits and during the
treatment phase. The cost categories included outpatient
visits, physician consultation, hospitalization, laboratory
tests, radiology and drugs. Cost per visit to a health care
provider were calculated and extrapolated for the entire
duration of treatment. Indirect costs were estimated from
time spent to access care including travel and hours spent
at the health facility. Time was then converted to a mo-
netary value based on average wages earned prior to the
diagnosis of TB as reported by the patients.
Health facility costs included outpatient clinics,
hospitalization and laboratory services. Existing hospital
and program accounting systems were reviewed and the
availability of cost and other data assessed. For all activ-
ities related to the treatment of tuberculosis health
facility and program resources were quantified and orga-
nized by categories including personnel, incentives, diag-
nostic test, monitoring and communication. The
program personnel time costs were estimated using
activity based costing (ABC). Time spent on activities
related to patient care was determined by interviews and
following personnel during their routine actives.
Personnel salaries were then allocated based on the time
spent for care of TB patients.
Costs were collected in Pakistan Rupees 2012 and con-
verted to US dollars using the average exchange rate for
the year by State Bank of Pakistan (1 USD = 93.29 PKR).
Cost data were analyzed using Stata (Stata Corp LP.
College Station, Texas). Costs were discounted at 3% as
recommended in the literature [25].
Decision and Markov model
The cost-effectiveness analysis compared costs and
health outcomes associated with all forms of TB diag-
nosed and treated either through active case finding or
passively at a TB center. A decision tree was created
with short-term outcomes. In this model, patients in the
active or passive case finding arm were identified as pre-
sumptive TB patients. People without TB symptoms
were not followed further. People with symptoms were
asked to test for TB. Patients found not to have TB were
not evaluated further in the model. Those diagnosed
with the disease were offered treatment (Fig. 1a).
The long-term outcomes of TB treatment for both
intervention arms were estimated by a Markov model
with four mutually exclusive health states; 1) TB treat-
ment, 2) well, 3) active TB and 4) death. Figure 1b repre-
sents the possible movements of patient between the
health states. In the model, patients started on “TB treat-
ment” either survived or died from TB. Surviving pa-
tients completed treatment, or defaulted to return to
active TB. Those that completed treatment achieved
cure and entered well state, or failed treatment and
returned to active TB. People in the “well state” survived
or died of natural causes. Those who survived either
remained well or acquired reinfection and entered TB
treatment cohort [26]. People in the “active TB” state
survived or died of disease. Those who survived either
achieved spontaneous cure and entered well state, or
returned to TB treatment. “Death” is an absorbing health
state, which occurred as disease outcome or as back-
ground mortality.
The long-term outcomes for TB positive patients not re-
ceiving treatment in both intervention arms were estimated
by a Markov model with three mutually exclusive health
states; 1) Active TB, 2) Well and 3) Death. The health
states and possible transitions are illustrated in Fig. 1c.
At the beginning of the first-year, health seekers in the
TB treatment arm are assumed to start in the TB
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treatment state, and with a mean age of 32 years (as
calculated from study data). The model was run for 40
cycles, each with a 6-month duration. Costs and out-
comes were calculated and cumulated after each cycle.
Transition probabilities
Most transition probabilities used in the model were es-
timated from an actual cohort of patients seen during
this project (Table 1 and Additional file 1: Table S1).
Probabilities for spontaneous resolution and relapse
after cure were estimated from published cohort studies
[21, 28–30]. Background mortality for the “Well” state
was estimated using a WHO life table for Pakistan [32],
whereas, TB specific mortality data generated from the
project was used for the “TB treatment” state [17]. Co-
morbidities such as HIV were not considered in the
model, as the prevalence of HIV is less than 1% in
Pakistan. Multi drug resistant TB was not considered as
Fig. 1 a Decision Tree of the model capturing the short-term outcomes of screening and testing. b State Transition Diagram illustrating the
Markov model capturing longer-term costs and health effects when TB patients receive treatment. c State Transition Diagram illustrating the
Markov model capturing longer-term costs and health effects for TB patients in the absence of treatment
Hussain et al. BMC Health Services Research          (2019) 19:690 Page 4 of 10
the project’s objective was to increase case detection
for susceptible TB.
Health outcome
Treatment outcomes were reported by the study. Health
benefits were estimated as disability-adjusted life years
(DALYs), based on disease weights for TB without HIV
using assumption from the Global Burden of Disease
2010 study [31] and were discounted at 3%.
Cost-effectiveness
As discussed above public and private sector in Pakistan
are parallel systems. Therefore, we treat both public and
private systems as independent interventions, and conse-
quently compared both strategies to a common baseline
of “no case finding” (patients found passively in the pub-
lic sector) [33]. The comparator “no case finding” repre-
sents a situation where TB patients remain unidentified
and consequently experience the natural path of the dis-
ease. While this is arguably an artificial situation, this
analytical approach enables the comparison of these in-
dependent interventions as well as comparison between
TB screening and health interventions in other parts of
the health services more broadly. The results are
presented as incremental costs, incremental benefits and
incremental cost-effectiveness ratios (ICERs) compared
to no case finding, expressed as cost (2012 USD) per
DALY averted.
Uncertainty and sensitivity analyses
Sensitivity analyses were conducted to explore the effects
of key parameters. Upper and lower values (+/− 20%) for
each parameter were estimated around mean value and
standard error (SE) was calculated by (upper-lower)/
(1.96*2) [25]. The model was designed by using TreeAge
Pro 2015 (TreeAge Pro Inc., Williamston, MA).
Table 1 Modeling inputs, assumptions and ranges of TB outcome for health states
Probability Active Case Finding arm
(lower and upper limit)
Passive Case Finding arm
(lower and upper limit)
Reference
Probability of TB Presumptive 0.022 (0.02–0.03) 0.046 (0.04–0.06) [17, 34]
Probability of TB Test 0.61 (0.49–0.73) 0.82 (0.66–0.98) [17, 34]
Probability of Positive TB test 0.08 (0.06–0.10) 0.13 (0.10–0.16) [17, 34]
Probability of starting TB treatment 0.94 (0.75–1.13) 0.94 (0.75–1.13) [17, 34]
Transition Probabilities
Probability of Successful TB treatment 0.77 (0.62–0.92) 0.75 (0.60–0.90) [17, 34]
Probability of Failing TB treatment 0.02 (0.01–0.02) 0.04 (0.03–0.05) [17, 34]
Probability of default during TB treatment 0.19 (0.15–0.23) 0.20 (0.16–0.24) [17, 34]
Probability of Death during TB treatment 0.02 (0.01–0.02) 0.01 (0.008–0.012) [17, 34]
Probability of dying from natural causes Life tables Life tables [26]
Probability of relapse after successful treatment 0.03 (0.02–0.04) 0.03 (0.02–0.04) [28]
Probability of mortality if no TB treatment 0.33 (0.26–040) 0.33 (0.26–0.40) [29]
Probability of spontaneous cure 0.25 (0.20–0.30) 0.25 (0.20–0.30) [30]
Cost
Cost of no TB symptom at screening $2.15 (1.72–2.58) $4.24 (3.39–5.09) Additional file 1: Table S1
Cost if no TB test with positive symptom $2.15 (1.72–2.58) $4.24 (3.39–5.09) Additional file 1: Table S1
Cost of screening and negative sputum test $7.15 (5.72–8.58) $11.24 (8.99–13.49) Additional file 1: Table S1
Cost of screening and no treatment if smear positive $82 (65.60–98.40) $48 (38.40–57.60) Additional file 1: Table S1
Cost of screening, tests and successful TB treatment $223 (178.40–267.60) $171 (136.80–205.20) Table 2
Cost of screening, testing and TB treatment before
loss to follow-up
$112 (89.60–134.40) $86 (68.80–103.20) Additional file 1: Table S1
(loss to follow up at 3 month
of TX)
Cost of screening, testing and TB treatment before
death from disease
$149 (119.20–178.80) $114 (91.20–136.20) Additional file 1: Table S1
(Death at 4 month of TX)
Disease weights (DWs)
DW for no TB treatment 0.0.331 (0.26–0.40) 0.0.331 (0.26–0.40) [31]
DW of well state 0 0
DW of death 1 1
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Ethical approval for the study was obtained from
Interactive Research and Development IRB.
IRB - IRD is registered with the U.S. Department of
Health and Human Services (DHHS) Office for Human
Research Protections (OHRP) with registration number
IRB 00005148.
Results
Probabilities of health seekers screened, tested, treatment
initiated and treatment outcome were obtained from the
larger study over a period of 2 years and reported for the
first year of study elsewhere (Table 1) [17, 34].
Of the 129 patients interviewed, males and females
were equally represented and most patients were be-
tween 15 and 44 years of age. The average household
size was 6.5 people. Over 50% of the patients had re-
ceived at least primary education. Only 30% of patients
were employed at the time of interview and 8% of these
experienced a decrease in income. In the ACF arm 52%
had smear negative TB whereas, 42% had smear negative
TB in the PCF arm.
The incentive-based ACF program incurred $223 per
patient treated (program: $164, patient: $59) whereas
$171 per patient (program: $100, patient: $71) was spent
at the PCF non-incentive arm. ACF resulted in 999 more
patients diagnosed and treated for TB as compared to
the passive arm at the cost of USD 272 per additional
patient. On average, it took at least 5 symptomatic visits
to a health facility at a cost of $4 per visit before smear
microscopy was requested in the passive arm as com-
pared to 2 visits at $2 per visit in the active case finding
arm. In the PCF arm, almost 50% of the direct out-of-
pocket expenditure by patients was pre-diagnosis of TB.
Combined the main cost drivers were non-TB medica-
tion (51%) and food and transport (33%). Indirect costs
for patients treated at the passive center were higher
than those treated at the private family clinics. In the
active case finding program substantial costs were spent
on personnel and incentives. A USD 40 per patient
incentive was provided to the health workers for case
detection and case holding. In the PCF arm, personnel
cost was the major cost driver (Table 2).
The project did not follow patients who were not cate-
gorized as presumptive TB patients, nor those who did
not provide specimen for sputum smear microscopy or
tested negative for TB. Costs associated with screening
these patients were estimated based on the total number
of people screened in each arm [34].
Cost-effectiveness
PCF when compared to no screening program costed
46.27 dollars per DALY saved. Whereas, ACF incremen-
tally averted 0.1699 DALYs at the cost of 15.74 over 6
months of treatment with TB drugs when compared to
baseline (Table 3).
Sensitivity analysis
A deterministic sensitivity analysis was performed for
each variable in the model where the parameters and
cost were varied over a predefined range (Table 1). In
Table 2 Provider and patient costs for TB screening, diagnosis
and treatment





(N = 1858) (N = 859)
Personnel 59 (36%) 44 (44%)
Incentive 40 (24%) 0 (0%)
Diagnostic Test 11 (7%) 11(11%)
Anti TB Drugs 22 (13%) 22 (22%)
Supervision and Monitoring 18 (11%) 9 (9%)
Marketing and communication 4 (2%) 6 (6%)
Training 0 (0%) 0 (0%)
Equipment 8 (5%) 8 (8%)
Mobile Xray Unit 2 (1%) 0 (0%)
Total provider cost per patient $164 $100





(N = 84) (N = 45)
Before diagnosis
No. of visits 2 5
Consultation 0.36 (1%) 3.45 (9%)
Test 1.6 (5%) 2.48 (6%)
Medication 4.62 (15%) 10.44 (26%)
Food and Transport 0.36 (1%) 3.19 (8%)
Diagnosis
Consultation 0.42 (1%) 0 (0%)
Test 1.55 (5%) 0.52 (1%)
Medication 12.72 (41%) 1.33 (3%)
Food and Transport 2.27 (7%) 3.03 (8%)
Treatment and follow up
Consultation 0.69 (2%) 0 (0%)
Test 0.6 (2%) 0 (0%)
Medication 3.2 (10%) 4.21 (11%)
Food and Transport 2.79 (9%) 11.73 (29%)
Subtotal direct cost $31 $40
Lost earnings $28 $31
Total cost per patient $59 $71
Total program cost per patient $223 $171
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the Tornado diagrams for active and passive case find-
ings variables are sorted according to their individual
potential impact on the ICER (Fig. 2). The ICER in both
arms was most sensitive to probability of being tested in
the PCF arm and if the test was positive, but the uncer-
tainty range for no individual variable was wide enough
to change the main result that ACF appear to be more
cost-effective than PCF. The uncertainty ranges in the
individual cost variables had relatively little impact on
cost-effectiveness.
Discussion
Our results indicate that incentive-based ACF in the pri-
vate sector is more cost-effective than PCF, and should
be considered if resources permit. Also PCF is highly
cost-effective when compared to a commonly applied
threshold of GDP per DALY averted [27]. We believe
PCF and ACF most appropriately should be considered
independent in the context of public and private health
sectors in Pakistan, respectively. Our analysis therefore
should not interpreted in favor of disinvestments of the
PCF scheme.
Even though the ACF model was over all more expen-
sive per patient treated; it had less out-of-pocket ex-
penditure with fewer health facility visits and better
outcomes for patients than those treated in the standard
passive system. People incurred substantial direct and
indirect costs to access care for TB in settings where
programs are otherwise said to be providing free TB
services [35–37]. A systematic review reports a mean
total patient cost ranging from $55 to $8198 with 20%
direct expenditure, 20% indirect medical expenditure
and 60% income loss, with over 50% of the costs
expected before TB treatment was initiated [38]. This is
very consistent with our findings that patients in Karachi
experienced half the cost prior to diagnosis and over
40% attributable to income loss. In line with WHO End
TB Strategy to ‘Zero TB-affected families facing
catastrophic costs’ [39], policies should focus on ensur-
ing that people with TB are identified early and are
supported to minimize out of pocket expenditure. The
ACF strategy used in this study doubled TB case notifi-
cation rates [17], took health care closer to people and
lead to earlier diagnosis at a reduced cost to the patient.
Evidence suggests that carefully planned and moni-
tored incentives strategies can increase case detection
and improve treatment completion rates and should be
considered to achieve TB control goals [15]. The incen-
tives in this program were divided over the care cycle
between screening, diagnosis and treatment adherence.
In addition, a strong monitoring process was put in
place to improve data quality. Our analysis suggests that
even with the high cost of incentive the ACF is still more
cost-effective. We therefore argue that in countries
where a substantial proportion of patients preferentially
seek care in the private sector, scaling up incentive
programs for screeners can be a cost-effective option to
increase case notifications.
Our results are consistent with results from other
countries such as Uganda and Cambodia that have
found active case finding interventions to be cost-effect-
ive [11, 12]. The analysis suggests that active case finding
is an effective strategy and should be instituted at health
facilities in Pakistan whenever resources are available.
This ACF program was conducted over a period of 2
years in a targeted setting in Karachi. A modelling study
in the same setting has demonstrated that if the active
case finding were to be sustained over a 5-year time
horizon it could decrease TB mortality by over 50% and
incidence of TB by 24% [34]. Whereas, models in China,
South Africa and India have demonstrated that ACF will
remain cost-effective even if the cost per case is USD
1000 [40]. Essentially, PCF provides certain level of
coverage in TB programs and then ACF is needed to
reach more people and to reach them earlier.
The strength of this analysis is that it draws on actual
cost and probability data collected as part of the study.
However, there are limitations; firstly, the out of pocket
expenditure costs is probably an underestimate and it is
unsure how the ICER might have been affected. We
calculated the indirect cost based on the travel time and
time spent at the health facility only for the person
seeking care. In our setting, this person is often accom-
panied by a family members thus increasing the costs
borne by the family. Second, we also could not get clear
estimates for time taken off from work during illness
and had to exclude this from indirect cost estimation.
WHO is testing a standardized Tuberculosis Patient
Table 3 Absolute and incremental costs, effect and cost-effectiveness from the patients, health facilities and the TB program
perspective. For both strategies, incremental values are calculated compared to a common baseline, i.e. no case finding
Strategy Cost/health seeker for symptoms of TB (USD) Incremental Cost DALYs Incremental DALYs Incremental C/E
No passive case finding 0 0.1806
Passive case finding 6.09 6.09 0.0491 0.1315 46.27
No active case finding 0 0.1806
Active case finding 2.67 2.67 0.0107 0.1699 15.74
The DALY is a negative outcome measure, meaning that less are better than more. Thus, the DALYs were inverted for computational reasons in this analysis
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Cost Surveys tools in several countries which will help
in estimating such costs. Third, we considered both
patient and provider costs, but from the provider’s per-
spective we only considered operational cost and did not
take capital expenditure into account for either arm of
the study. Our findings may not be non-generalizable to
countries where ACF and PCF strategies are undertaken
by the same sector simultaneously. Studies have shown
that ACF can identify people with TB earlier and there-
fore potentially reducing TB transmission [12, 34]. Our
static model is not well suited to include effects of TB
transmission, but our conclusion that ACF is cost-effective
can be argued to be conservative since incorporation
of reduced transmission would have made it even
more favorable. It is also possible that the use of stand-
ard disease weight for TB from the Global Burden of
Disease in this model overestimate the disease burden
in the active arm. Especially if the patients in the pas-
sive arm on average are detected later and with more
progressed disease than patients in the active arm. To
the extent that this potential selection problem affect
long term outcomes, we believe that the model still
holds true as transition probabilities are informed by
real study data.
Fig. 2 Tornado ICER diagram of active case finding as compared to passive case
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Conclusion
Our results shows that incentive-driven active case-find-
ing in the private sector is cost-effective and should be
added on to the routine passive case-finding in this set-
ting if resources are available.
Additional file
Additional file 1: Table S1. Ingredient Costing. Ingredient cost used to
calculate each cost parameter in active and passive case finding arms.
(DOCX 68 kb)
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